Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of$ 0.76. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.67 per share when it actually produced a loss of $0.81, delivering a surprise of -20.90%.Over the last four quarters, the ...